University of Wisconsin–Madison researchers have recently revealed that the effectiveness of common antibiotics could depend on the neighborhood where you live. Here are the details.
Research
Brain-Penetrating Drug Candidate Effective Against Deadly Encephalitis Viruses
A new antiviral compound designed and synthesized by researchers at the University of Wisconsin–Madison’s School of Pharmacy is highly effective in mice against two types of devastating encephalitis viruses that are harmful to humans.
New Drug Delivery Method Harnesses Clotting to Target Anti-Cancer Drugs at Tumors
Assistant Professor Quanyin Hu has developed a new method for targeting tumors with cancer drugs by exploiting the clotting propensity of blood platelets.
Leading Lab in Photos: Behind the Scenes in the Li Research Group
See the people, processes, and equipment fueling Professor Lingjun Li’s internationally recognized research program.
Preventing the Next Pandemic
From COVID-19 to encephalitic alphaviruses, School of Pharmacy Associate Professor Jennifer Golden and collaborators are developing new antiviral treatments.
A Source of HOPE
With funding from the American Diabetes Association, Professor Eva Vivian launches a study to help African American grandmothers initiate generational change in diabetes prevention.
Innovating Pulmonary Treatments for Preemies
Funded by multiple grants, alum Russ Lehrman (PhD ‘81) is developing a new therapeutic to revolutionize pulmonary care, starting with preterm infants.
School of Pharmacy Researchers Earn 2022 Best Paper Award for Pioneering CancelRx Study
The winning paper by Professor Michelle Chui, alum Taylor Watterson (MS ’18, PhD ’22) and collaborators explores impactful changes to pharmacist and prescriber workflow.
Killing Infection with Infection
Through new NIH grant, School of Pharmacy Assistant Professor Jason Peters and collaborators are investigating bacteria viruses as a way to defeat antibiotic resistance.
Two First-in-Kind Clinical Trials Explore Psilocybin for Substance Misuse
Professor Paul Hutson and collaborators in the Transdisciplinary Center for Research in Psychoactive Substances study psilocybin for opioid and methamphetamine use disorders.